IP Barriers Block Pfizer Following US Pegfilgrastim Approval

Sixth Oncology Biosimilar Approval Chalked Up

 
• By Dean Rudge
  
PfizerSign
Pfizer's biosimilar portfolio now includes six FDA-approved oncology products • Source: Shutterstock

More from Biosimilars

More from Products